A novel highly selective allosteric inhibitor of tyrosine kinase 2 (TYK2) can block inflammation- and autoimmune-related pathways

被引：0

作者：

Celia X.-J. Chen

Wei Zhang

Shulan Qu

Fucan Xia

Yidong Zhu

Bo Chen

机构：

[1] Shanghai Qilu Pharmaceutical R&D Center Limited,Department of Immunology and Inflammation

[2] Present address: China Resources Pharmaceutical Group Limited,undefined

来源：

Cell Communication and Signaling | / 21卷

关键词：

TYK2; JAK; Cytokine pathway; Pseudokinase regulatory domain; Allosteric inhibitor; Psoriasis; Autoimmune diseases;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[1] A novel highly selective allosteric inhibitor of tyrosine kinase 2 (TYK2) can block inflammation- and autoimmune-related pathways
Chen, Celia X. -J.
Zhang, Wei
Qu, Shulan
Xia, Fucan
Zhu, Yidong
Chen, Bo
CELL COMMUNICATION AND SIGNALING, 2023, 21 (01)
[2] IN-121803, a novel highly selective allosteric inhibitor of tyrosine kinase 2 (TYK2) for the treatment of autoimmune disease
Chung, H.
Park, J.
Tae, Y.
Hwang, I.
Park, C.
Kim, J.
Lee, K.
Kim, J.
Kim, D.
Kim, H.
Kim, B.
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2024, 144 (08) : S95 - S95
[3] Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165
Wrobleski, Stephen T.
Moslin, Ryan
Lin, Shuqun
Zhang, Yanlei
Spergel, Steven
Kempson, James
Tokarski, John S.
Strnad, Joann
Zupa-Fernandez, Adriana
Cheng, Lihong
Shuster, David
Gillooly, Kathleen
Yang, Xiaoxia
Heimrich, Elizabeth
McIntyre, Kim W.
Chaudhry, Charu
Khan, Javed
Ruzanov, Max
Tredup, Jeffrey
Mulligan, Dawn
Xie, Dianlin
Sun, Huadong
Huang, Christine
D'Arienzo, Celia
Aranibar, Nelly
Chiney, Manoj
Chimalakonda, Anjaneya
Pitts, William J.
Lombardo, Louis
Carter, Percy H.
Burke, James R.
Weinstein, David S.
JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (20) : 8973 - 8995
[4] Tyrosine Kinase 2 (TYK2) Allosteric Inhibitors To Treat Autoimmune Diseases
Chang, Yu
Xu, Shilin
Ding, Ke
JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (20) : 8951 - 8952
[5] Targeting the Tyrosine Kinase 2 (TYK2) Pseudokinase Domain: Discovery of the Selective TYK2 Inhibitor ABBV-712
Breinlinger, Eric
Van Epps, Stacy
Friedman, Michael
Argiriadi, Maria
Chien, Ellen
Chhor, Gekleng
Cowart, Marlon
Dunstan, Theresa
Graff, Candace
Hardee, David
Herold, J. Martin
Little, Andrew
Mccarthy, Richard
Parmentier, Julie
Perham, Matthew
Qiu, Wei
Schrimpf, Michael
Vargo, Thomas
Webster, Matthew P.
Wu, Fei
Bennett, Dawn
Edmunds, Jeremy
JOURNAL OF MEDICINAL CHEMISTRY, 2023, 66 (20) : 14335 - 14356
[6] Discovery of a Potent and Subtype-Selective Tyk2 Degrader Based on an Allosteric Tyk2 Inhibitor
Kato, Jun-Ya
Korenaga, Shigeru
Iwakura, Masaru
SSRN, 2022,
[7] Discovery of a potent and subtype-selective TYK2 degrader based on an allosteric TYK2 inhibitor
Kato, Jun-ya
Korenaga, Shigeru
Iwakura, Masaru
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2023, 79
[8] Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases
Gerstenberger, Brian S.
Ambler, Catherine
Arnold, Eric P.
Banker, Mary-Ellen
Brown, Matthew F.
Clark, James D.
Dermenci, Alpay
Dowty, Martin E.
Fensome, Andrew
Fish, Susan
Hayward, Matthew M.
Hegen, Martin
Hollingshead, Brett D.
Knafels, John D.
Lin, David W.
Lin, Tsung H.
Owen, Dafydd R.
Saiah, Eddine
Sharma, Raman
Vajdos, Felix F.
Xing, Li
Yang, Xiaojing
Yang, Xin
Wright, Stephen W.
JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (22) : 13561 - 13577
[9] Selective Tyrosine Kinase 2 (TYK2) Inhibition in Plaque Psoriasis
Kircik, Leon
Aldredge, Lakshi M.
DiRuggiero, Douglas
JOURNAL OF DRUGS IN DERMATOLOGY, 2024, 23 (08) : 645 - 652
[10] Discovery of WD-890: A novel allosteric TYK2 inhibitor for the treatment of multiple autoimmune diseases
Fang, Zhiqin
Sun, Hongyin
Wang, Yutong
Sun, Zhenliang
Yin, Mingzhu
BIOMEDICINE & PHARMACOTHERAPY, 2023, 167

← 1 2 3 4 5 →